Plain-English translation of NCT05692180 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Asthma research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether , a new injectable medication, can help children with severe eosinophil-driven asthma have fewer asthma attacks. Children with this type of asthma have high levels of immune cells called eosinophils in their airways, which can make their asthma hard to control even with strong medications. This treatment is designed to reduce those eosinophils and help prevent asthma exacerbations.
Children with severe eosinophil-driven asthma still have frequent asthma attacks and symptoms even when taking high-dose standard asthma medications. This medication was developed to target the specific immune process behind this type of asthma, offering hope for better control and fewer emergency visits or hospital stays.
You likely qualify if…
You likely don't qualify if…
You will have screening visits over 2–12 weeks to confirm you are eligible, then be randomly assigned to receive either the new medication or a placebo injection. Both groups will receive injections under the skin at scheduled visits. You will continue in the main study phase for at least 16 weeks (minimum) or until you have an asthma attack, whichever comes first. If you have an exacerbation, you can continue into an extension phase to receive at least 48 additional weeks of the active treatment, with follow-up visits and symptom tracking throughout.
AI-generated summary from trial data · Jun 17, 2026 · Not medical advice
United States